CDK6 and lung adenocarcinoma: Buss et al. (2012) reported that CDK6 directly regulates p65 phosphorylation in the cytoplasm and nucleus, identifying it as an S536-specific NF-κB kinase. In an Eμ-v-cyclin transgenic mouse model, increased levels of CDK6, phosphorylated p65 S536, NF-κB activity and thymic and splenic lymphoma formation suggest that CDK6 promotes tumorigenesis through NF-κB. Furthermore, in lung adenocarcinoma, GSK-3β was found to phosphorylate S536 and activate NF-κB transcription (Cheng et al., 2021).